Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

计划入组 75 人 · 首次发布于 2020 年 5 月 22 日

Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

计划入组 44 人 · 首次发布于 2017 年 11 月 7 日

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

计划入组 256 人 · 首次发布于 2020 年 3 月 25 日

Dgat2-1473

IONIS-DGAT2Rx

DGAT1 inhibitors (obesity)

Pfizer's Novel MASH Treatment Combination Clesacostat/Ervogastat Projects $16M Revenue by 2036

Cholinergic Regulation of Neuroinflammation: Microglia, Immunometabolism, and Therapeutic Frontiers